Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie Inc. (ABBV). The two companies announced a collaboration and option-to ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

XLO opened at $0.73 on Thursday ... beating the consensus estimate of ($0.22) by $0.02. The firm had revenue of $1.72 million for the quarter, compared to analyst estimates of $2.26 million.

Short interest in Xilio Therapeutics Inc (NASDAQ:XLO) increased during the last reporting period, rising from 575.45K to 644.54K. This put 1.46% of the company's publicly available shares short.

ByInvesting.com • Apr 08, 2025 XLO stock touches 52-week low at $0.62 amid market challenges In a challenging market environment, Xilio Development’s stock (XLO) has recorded a new 52-week low ...